Metastatic extent predicts survival as patients with metastatic castration-resistant prostate cancer are treated with (177)Lu-PSMA radioligand therapy

PSMA based radioligand is a new investigational drug for treatment of metastatic multidrug-resistant and castration-resistant prostate cancer. Prognostic factors point to above and below average overall survival (OS) after the treatment. Kessel et al. [Theranostics 2019;9:4841-8] reported for the fi...

Descripción completa

Detalles Bibliográficos
Autores principales: von Eyben, Finn Edler, Kulkarni, Harshad R., Baum, Richard P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2020
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7163457/
https://www.ncbi.nlm.nih.gov/pubmed/32308757
http://dx.doi.org/10.7150/thno.44568
_version_ 1783523217776836608
author von Eyben, Finn Edler
Kulkarni, Harshad R.
Baum, Richard P.
author_facet von Eyben, Finn Edler
Kulkarni, Harshad R.
Baum, Richard P.
author_sort von Eyben, Finn Edler
collection PubMed
description PSMA based radioligand is a new investigational drug for treatment of metastatic multidrug-resistant and castration-resistant prostate cancer. Prognostic factors point to above and below average overall survival (OS) after the treatment. Kessel et al. [Theranostics 2019;9:4841-8] reported for the first time that two sites of visceral metastases, lungs and liver, differed in impact on OS after treatment with (177)Lu PSMA 617. Treatment with established drugs showed the same trend. The difference in OS between the sites is independent of the type of treatment and can reflect changes in tumor biology during the progression of metastatic prostate cancer.
format Online
Article
Text
id pubmed-7163457
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Ivyspring International Publisher
record_format MEDLINE/PubMed
spelling pubmed-71634572020-04-17 Metastatic extent predicts survival as patients with metastatic castration-resistant prostate cancer are treated with (177)Lu-PSMA radioligand therapy von Eyben, Finn Edler Kulkarni, Harshad R. Baum, Richard P. Theranostics Editorial PSMA based radioligand is a new investigational drug for treatment of metastatic multidrug-resistant and castration-resistant prostate cancer. Prognostic factors point to above and below average overall survival (OS) after the treatment. Kessel et al. [Theranostics 2019;9:4841-8] reported for the first time that two sites of visceral metastases, lungs and liver, differed in impact on OS after treatment with (177)Lu PSMA 617. Treatment with established drugs showed the same trend. The difference in OS between the sites is independent of the type of treatment and can reflect changes in tumor biology during the progression of metastatic prostate cancer. Ivyspring International Publisher 2020-03-30 /pmc/articles/PMC7163457/ /pubmed/32308757 http://dx.doi.org/10.7150/thno.44568 Text en © The author(s) This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
spellingShingle Editorial
von Eyben, Finn Edler
Kulkarni, Harshad R.
Baum, Richard P.
Metastatic extent predicts survival as patients with metastatic castration-resistant prostate cancer are treated with (177)Lu-PSMA radioligand therapy
title Metastatic extent predicts survival as patients with metastatic castration-resistant prostate cancer are treated with (177)Lu-PSMA radioligand therapy
title_full Metastatic extent predicts survival as patients with metastatic castration-resistant prostate cancer are treated with (177)Lu-PSMA radioligand therapy
title_fullStr Metastatic extent predicts survival as patients with metastatic castration-resistant prostate cancer are treated with (177)Lu-PSMA radioligand therapy
title_full_unstemmed Metastatic extent predicts survival as patients with metastatic castration-resistant prostate cancer are treated with (177)Lu-PSMA radioligand therapy
title_short Metastatic extent predicts survival as patients with metastatic castration-resistant prostate cancer are treated with (177)Lu-PSMA radioligand therapy
title_sort metastatic extent predicts survival as patients with metastatic castration-resistant prostate cancer are treated with (177)lu-psma radioligand therapy
topic Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7163457/
https://www.ncbi.nlm.nih.gov/pubmed/32308757
http://dx.doi.org/10.7150/thno.44568
work_keys_str_mv AT voneybenfinnedler metastaticextentpredictssurvivalaspatientswithmetastaticcastrationresistantprostatecanceraretreatedwith177lupsmaradioligandtherapy
AT kulkarniharshadr metastaticextentpredictssurvivalaspatientswithmetastaticcastrationresistantprostatecanceraretreatedwith177lupsmaradioligandtherapy
AT baumrichardp metastaticextentpredictssurvivalaspatientswithmetastaticcastrationresistantprostatecanceraretreatedwith177lupsmaradioligandtherapy

Ejemplares similares